Loading clinical trials...
Loading clinical trials...
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Carrelizumab + chemotherapy + apatinib
Start Date
July 7, 2021
Primary Completion Date
December 12, 2023
Completion Date
April 4, 2024
Last Updated
July 6, 2021
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
NCT05005403
Lead Sponsor
Beijing Chest Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions